

COMMUNITY PHARMACEUTICAL DISPENSING PERIOD EXEMPTIONS
Section F PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

- (a) is exempt from any requirement to dispense in Monthly Lots;
- (b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is Close Control.

Section F PART II: Certified Exemptions and Access Exemptions to Monthly Dispensing
 A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

- (a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber has endorsed the Prescription item(s) on the Prescription to which the exemption applies "certified exemption" or signed or initialled the prescription item(s) in his/her own handwriting. In endorsing the Prescription items for a certified exemption, the prescriber is certifying that:
 - (i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
 - (ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
 - (iii) the prescriber has reason to believe the patient will continue on the medicine and is compliant;
- (b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient must also certify which of the following criteria they meet:
 - (i) have limited physical mobility;
 - (ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - (iii) are relocating to another area;
 - (iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

INSULIN	VASOPRESSIN AGONISTS
Insulin – Short-acting Preparations	Desmopressin
Insulin neutral	Nasal spray 10 µg per dose, 50 dose
Insulin animal	Nasal drops 100 µg per ml
Insulin – Intermediate and Long- acting Preparations	ANTICHOLINESTERASES
Insulin isophane	Pyridostigmine bromide
Insulin isophane with insulin	CONTROL OF EPILEPSY
Neutral	New Antiepilepsy Drugs
Insulin zinc suspension	Gabapentin
Insulin animal	Lamotrigine
INSULIN – Rapid-acting insulin analogues	Topiramate
Insulin lispro	Vigabatrin
ANTIARRHYTHMICS	DOPAMINE AGONISTS AND RELATED AGENTS
Amiodarone hydrochloride	Amantadine hydrochloride

Tab 100 mg Tab 200 mg Disopyramide phosphate Flecainide acetate Tab 50 mg Tab 100 mg Cap long-acting 100 mg Cap long-acting 200 mg Mexiletine hydrochloride Propafenone hydrochloride	Apomorphine hydrochloride Lisuride hydrogen maleate Pergolide Tolcapone GLAUCOMA PREPARATIONS Latanoprost
--	--

Section A, Part 1 Interpretation and definitions

“90 Day Lot” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 90 consecutive days’ treatment;

“Access Exemption Criteria” means the criteria under which patients may receive greater than one Month’s supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

“Close Control” means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, as applicable, where all of the following conditions are met:

- a) the Community Pharmaceutical is a tri-cyclic antidepressant, antipsychotic, benzodiazepine, a Class B Controlled Drug, or any other Community Pharmaceutical that has been prescribed for a patient who:
 - (i) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and
 - (ii) in the opinion of the prescribing Doctor, Midwife or Nurse Prescriber is:
 - A) frail; or
 - B) infirm; or
 - C) unable to manage their medication without additional support; or
 - D) intellectually impaired; and
 - (iii) requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded; and
- b) the prescribing Doctor, Midwife or Nurse Prescriber has
 - (i) endorsed each Community Pharmaceutical on the Prescription clearly with the words “close control” or “CC”; and
 - (ii) initialled the endorsement in the prescribers own handwriting; and
 - (iii) specified the maximum quantity or period of supply to be dispensed at any one time.

“Monthly Lot” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 30 consecutive days’ treatment;

“Penal Institution” means a penal institution, as that term is defined in The Penal Institutions Act 1954;

“Residential Disability Care Institution” means:

- a) premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001; and
- b) up to and including October 2004, a home, as that term is defined in the Disabled Persons Community Welfare Act 1975;

“Rest Home” means:

- a) premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001; and
- b) up to and including October 2004, a home, as that term is defined in the Old People’s Homes Regulations 1987;

“Section F Part I” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots, and requirement to dispense in 90 Day Lots, in respect of the Community Pharmaceuticals referred to in this part of Section F;

“Section F Part II” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots in respect of the Community Pharmaceuticals referred to in this part of Section F;

Section A, Part III Period and Quantity of Supply

3.1.4 Subject to clauses 3.1.3 and 3.1.7, where a Doctor, Midwife or Nurse Prescriber has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:

- a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
- b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - 1) the Practitioner endorses the Community Pharmaceutical on the Prescription with the words “certified exemption” written in the Practitioner’s own handwriting or signed or initialled by the Practitioner; and
 - 2) every Community Pharmaceutical endorsed as “certified exemption” is covered by Section F Part II of the Pharmaceutical Schedule.

3.1.7 If a Community Pharmaceutical:

- a) is stable for a limited period only, and the Doctor, Midwife, or Nurse Prescriber has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is Close Control,
- the actual quantity dispensed will be subsidised in accordance with any such specification.